What Artivion does

Artivion, Inc. (NYSE: AORT; founded 1984 as CryoLife, rebranded 2021) is a biological medical device company headquartered in Kennesaw, Georgia, that develops, manufactures, and markets implantable tissues and medical devices used in cardiac and vascular surgery, with primary focus on aortic disease. Its product portfolio is organized into five categories: heart valves (ON-X mechanical mitral and aortic valves, CHORD-X chordal replacement, CryoValve cryopreserved allografts); allografts (CryoPatch, CryoGraft, CryoArtery, CryoVein for cardiac and vascular reconstruction); aortic arch solutions (NEXUS, NEXUS TRE, NEXUS DUO endovascular stent grafts from Endospan; AMDS Hybrid Prosthesis from Ascyrus; Neo EDE, E-vita Open Neo hybrid systems); thoracoabdominal and abdominal stent grafts (E-xtra Design MultiBranch, E-nside TAAA, Artivex, E-tegra, E-liac); and surgical sealants and accessories (BioGlue surgical adhesive, PhotoFix decellularized bovine pericardium, CO2 diffusers, guidewires, balloon catheters, vascular grafts). Underlying technology centers on proprietary manufacturing methods including SynerGraft decellularization, photo-oxidization crosslinking, custom-made multibranch stent graft engineering, and Frozen Elephant Trunk hybrid graft systems, each supported by published clinical outcomes such as 20-year CryoValve endocarditis freedom (85.2%), 1-year NEXUS TRIOMPHE survival (94%), and 2-year AMDS PERSEVERE remodeling data.

Artivion monetizes its portfolio through two reporting segments: Medical Devices (hardware sales of stent grafts, valves, sealants, and accessories) and Preservation Services (human tissue allograft distribution including heart valves, veins, arteries, and patches). Pricing is quote-based and contract-negotiated with hospitals and is not publicly disclosed. The company operates an enterprise field sales model in the U.S. calling directly on hospitals with cardiac surgery programs, complemented by an international distributor network and wholly-owned regional entities (JOTEC GmbH in Germany, On-X Life Technologies in Austin, Ascyrus Medical in Frankfurt, Artivion EMEA GmbH in Switzerland, and Endospan in Israel, acquired May 2026). Marketing channels are dominated by participation in major cardiac and vascular surgery congresses (AATS, STS, EACTS, VEITH, ESVS), KOL-led medical education webinars, ELITE surgeon training events, and clinical trial presentations, targeting cardiac and vascular surgeons as the primary economic buyer and end user.

The regulatory and clinical evidence base forms the core competitive moat: FDA Pre-Market Approval for NEXUS (April 2026), FDA Humanitarian Device Exemption for AMDS (December 2024), SynerGraft 510(k) clearance for CryoValve SG pulmonary valve, and aggregated long-term clinical data spanning up to 20 years underpin premium device positioning. Major customers span thousands of cardiac surgery hospitals globally rather than concentrated enterprise accounts, with named clinical partners including Boston Children's Hospital (PhotoFix use), Athens Medical Center, St Thomas Hospital London, University Hospital Würzburg, and PERSEVERE trial investigators across the U.S. and Canada. Reported Q1 2026 revenue of $116.3 million (+12% YoY) and FY2026 guidance of $480-$496 million (7-11% constant currency growth, lowered for supply chain and AMDS starter set headwinds) reflect a $400M+ annualized run-rate business with active growth investment and a recent $175M acquisition (plus up to $200M in earnouts) extending its aortic arch portfolio.

Name

Artivion

Legal name

Artivion, Inc.

Website

https://artivion.com

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Artivion is a public biological medical device company (NYSE: AORT) that develops, manufactures, and markets implantable tissues and cardiac/vascular surgical devices — including aortic stent grafts, mechanical and cryopreserved heart valves, BioGlue surgical adhesive, and decellularized allografts — sold directly to hospitals and cardiac and vascular surgeons worldwide.

Ownership category

akta.pro rank

Product category

Cardiovascular Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Blood and Organ Banks (621991), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

akta.pro secondary industries

Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Aortic stent grafts
• Mechanical heart valves
• Cardiac surgery devices
• Vascular surgical adhesives
• Human tissue allografts

Headquarters

HQ city

Kennesaw

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Medical Device Sales: Artivion generates revenue primarily through the sale of implantable medical devices including heart valves, stent grafts, vascular grafts, and surgical adhesives to cardiac and vascular surgeons in hospitals globally.
2. Preservation Services: The company operates a Preservation Services segment providing cryopreserved human tissue allografts including heart valves, veins, arteries, and patches for surgical procedures.
3. Surgical Sealants and Adjuncts: Sale of surgical sealants like BioGlue and ancillary products including CO2 diffusers, guidewires, and balloon catheters.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Artivion is a biological medical device company that develops, manufactures, and sells implantable medical devices and human tissue products for cardiac and vascular surgeons. Its portfolio includes mechanical heart valves (On-X), surgical sealants (BioGlue), cryopreserved and decellularized human tissue allografts (CryoValve, CryoVein, CryoArtery, CryoPatch), and an extensive line of endovascular and hybrid stent graft systems for aortic arch, thoracoabdominal, abdominal, and peripheral aortic disease (NEXUS, AMDS, E-vita Open Neo, E-tegra, E-liac, E-nside, Neo EDE). The company sells directly to hospitals in the U.S. and through distributors internationally.

Product overview

Artivion is a medical device company specializing in cardiac and vascular surgical products for aortic disease treatment. The portfolio comprises five core product categories: (1) Heart Valves including ON-X mechanical valves (mitral and aortic), CHORD-X chordal replacement, and CRYOVALVE allografts (pulmonary and aortic); (2) Allografts including CRYOPATCH patches, CRYOGRAFT thoracic aorta, CRYOARTERY arteries, and CRYOVEIN veins for various reconstructive procedures; (3) Aortic Arch Solutions including the acquired NEXUS platform (NEXUS, NEXUS TRE, NEXUS DUO), AMDS Hybrid Prosthesis, NEO EDE device, and E-vita Open Neo hybrid system; (4) Stent Grafts spanning thoracoabdominal (E-xtra Design MultiBranch, E-nside TAAA), thoracic (Artivex), and abdominal (E-tegra, E-liac) applications; (5) Surgical Sealants and Accessories including BIOGLUE surgical adhesive, PHOTOFIX pericardium, CO2 diffusers, guidewires, balloon catheters, and vascular grafts. The company operates two segments: Medical Devices and Preservation Services.

Differentiator

Problem solved

Functional benefit

Brands

• BioGlue: Surgical adhesive for sealing, adhering and reinforcing tissue in cardiac and vascular surgery
• NEXUS
• AMDS
• CryoPatch
• CryoVein
• CryoArtery
• CryoValve
• On-X
• JOTEC

Products and services

• On-X Mitral Heart Valve Mechanical heart valve designed for mitral valve replacement with advanced hemodynamic features, for cardiac surgeons performing mitral valve replacement procedures.
• On-X Aortic Heart Valve Mechanical heart valve designed for aortic valve replacement with documented clinical outcomes for younger AVR patients, including post-approval study 5-year data.
• On-X Ascending Aortic Prosthesis Ascending aortic graft prosthesis designed for aortic root and ascending aorta reconstruction, used by cardiac surgeons in valve-sparing aortic root replacement procedures.
• Chord-X Mitral Chordal Replacement Products Mitral chordal replacement system with pre-measured loops and adjustable suture systems designed to simplify and standardize mitral valve repair procedures for cardiac surgeons.
• CryoValve SG Pulmonary Human Heart Valve First and only decellularized human heart valve to receive FDA 510(k) clearance, featuring SynerGraft technology that virtually eliminates allogeneic donor cells while maintaining structural integrity; for cardiac surgeons in pulmonary valve replacement.
• CryoValve Aortic Allograft Cryopreserved aortic heart valve allograft ideal for endocarditis patients, with documented 85.2% freedom from recurrent endocarditis at 20 years.
• CryoPatch SG Pulmonary Patch Decellularized bovine pericardial patch utilizing SynerGraft technology for pulmonary patch reconstruction in congenital cardiac surgery.
• CryoPatch Autologous Pericardium Cryopreserved autologous pericardium for cardiovascular reconstruction, widely used in pediatric cardiac surgery with low immunogenicity.
• CryoGraft Descending Thoracic Aorta Cryopreserved descending thoracic aorta allograft for cardiovascular reconstruction with natural suturability and compliance.
• CryoArtery Aortoiliac Artery Cryopreserved aortoiliac artery allograft for infected field replacement, demonstrating 96% freedom from reinfection at 5 years.
• CryoArtery Femoral Artery Cryopreserved femoral artery allograft for peripheral bypass in patients at risk of infection or with Critical Limb Ischemia, demonstrating 100% freedom from infection at 3 years.
• CryoVein Saphenous Vein Cryopreserved saphenous vein allograft for below-knee revascularization in patients with Critical Limb Ischemia, demonstrating 87% primary patency at 1 year and 70% limb salvage at 4 years.
• CryoVein Femoral Vein Cryopreserved femoral vein allograft ideal for patients with infected synthetic AV access grafts, demonstrating 72% 2-year cumulative patency.
• CryoVein PC Pediatric Conduit Cryopreserved pediatric conduit demonstrating improved pulmonary artery growth compared to PTFE grafts and natural flexibility allowing the allograft to stretch as the heart grows.
• Neo EDE Hybrid Arch Device Custom-made hybrid arch device designed to simplify complex Frozen Elephant Trunk procedures, with outer or inner branches for supra-aortic vessel implantation.
• AMDS Hybrid Prosthesis World's first aortic arch remodeling device for treating acute DeBakey Type I aortic dissections with malperfusion, combining PTFE felt cuff with uncovered nitinol wire braided stent; FDA HDE approved December 2024.
• NEXUS Aortic Arch Stent Graft System Endovascular aortic arch repair system specifically designed for the aortic arch with bimodular design and 20F low profile delivery system; FDA PMA approved April 2026.
• NEXUS TRE Aortic Arch Stent Graft System Custom-made total endovascular aortic arch repair solution enabling 100% percutaneous treatment, eliminating need for supra-aortic debranching with three-vessel feeding configuration.
• NEXUS DUO Aortic Arch Stent Graft System Custom-made double branch aortic arch stent graft designed to mitigate stroke risk, built on NEXUS technology with proprietary Dock & Lock technology.
• E-vita Open Neo Hybrid Stent Graft System Next-generation hybrid graft system for aortic arch and descending thoracic aorta repair with Frozen Elephant Trunk technique, featuring three configurations and compact delivery system.
• E-xtra Design MultiBranch Stent Graft System Custom-made patient-specific multibranch stent graft system for thoracoabdominal aneurysms and complex aortic pathologies, producible in 22 working days.
• E-nside TAAA Multibranch Stent Graft System First pre-cannulated inner branch-based off-the-shelf solution for thoracoabdominal aneurysms, designed to minimize fluoroscopy, implantation time, and contrast media.
• Artivex Thoracic Extension Stent Graft System Custom-made thoracic extension stent graft system engineered for stable and accurate connection with strong taper up to 20mm and impressive longitudinal stability.
• E-tegra Stent Graft System Abdominal aortic aneurysm stent graft system featuring W-shaped proximal stent design, 360-degree asymmetrical spring flexibility, and oval-shaped bifurcation spring for improved patency.
• E-liac Stent Graft System Iliac branch device for aorto-iliac and isolated iliac aneurysms, featuring high patency rates and low reintervention rates with asymmetric spring configuration.
• Artivion Tuva BX Peripheral Stent ePTFE covered peripheral stent with high flexibility, open cell design, and nested peaks to avoid strut-to-strut contact for treating tortuous arteries.
• BioGlue Surgical Adhesive The only surgical sealant approved to seal, adhere, and reinforce tissue, demonstrated to be significantly stronger than PREVELEAK, Coseal, and Tridyne in artery burst tests.
• PhotoFix Decellularized Bovine Pericardium Photo-oxidized decellularized bovine pericardium using dye-mediated photo-oxidation that eliminates toxic aldehyde by-products and creation of calcium-binding sites, used for tissue repair.
• CarbonAid and CarbonMini CO2 Diffuser CO2 diffusers designed to reduce risk of air embolism during open heart surgery by replacing air with greater than 99% CO2 in the surgical wound cavity.
• E-wire Guidewire Coated extra stiff 0.035 inch guide wire for catheter-based diagnostic and interventional procedures with short flexible tip for accurate positioning and X-ray visibility.
• FlowLine Bipore Vascular Graft ePTFE vascular graft with bipore design featuring two different fibril lengths for low thrombogenicity and printed guideline indicating diameter and wall thickness.
• E-xpand Stent Graft Balloon Catheter Compliant balloon catheter expandable up to 50mm with short inflation and deflation times, compatible with 0.035 inch guide wires and radiopaque markers for precise placement.
• FlowNit Bioseal Vascular Graft Knitted vascular graft with Bioseal impregnation featuring high burst strength, low dilatation, and texturized yarn for superior tissue incorporation, available in straight tubes and bifurcations.
• FlowWeave Bioseal Vascular Graft Woven vascular graft with Bioseal impregnation featuring high burst strength, low dilatation, and concentric crimping for safe positioning.

Quantifiable outcome

• NEXUS TRIOMPHE pivotal trial: 94% survival from lesion-related death and 91% freedom from disabling stroke at 1 year
• +6 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Endospan Ltd.coreStrategic or Co-development Partner · 18 May 2026Artivion completed acquisition of Endospan Ltd. for $175 million (plus offsets for previously provided loans) plus up to $200 million in contingent payments tied to U.S. NEXUS commercial performance over two years. Endospan is a pioneer in endovascular repair of aortic arch disease and developer of the NEXUS Aortic Arch System. Acquisition positions Artivion as the only company globally with a complete portfolio of aortic arch solutions.
• Ascyrus Medical GmbHcoreOEM/ Whitelabel/ Licensing PartnerAscyrus Medical GmbH is a wholly-owned subsidiary of Artivion, manufacturing the AMDS Hybrid Prosthesis - the world's first aortic arch remodeling device for acute DeBakey Type I dissections.
• JOTEC GmbHcoreOEM/ Whitelabel/ Licensing PartnerJOTEC GmbH is a wholly-owned subsidiary of Artivion based in Hechingen, Germany, providing European operations and manufacturing of vascular products including E-vita Open Neo, E-tegra, E-liac, and E-nside stent graft systems.
• Cardia Innovation ABminorChannel Partner/ Reseller/ DistributorCardia Innovation AB manufactures CarbonAid and CarbonMini CO2 diffuser products which are distributed by Artivion. Products reduce risk of air embolism during open heart surgery.
• Life Vascular Devices Biotech S.L.minorOEM/ Whitelabel/ Licensing PartnerLife Vascular Devices Biotech S.L. manufactures the Tuva BX peripheral stent graft, a product in Artivion's portfolio for treating peripheral aorta conditions.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medtronic: Global medical device leader with a deep cardiovascular portfolio spanning aortic stent grafts (Valiant/Talent), heart valves, and endovascular solutions. Directly overlaps with Artivion across thoracoabdominal and abdominal aortic repair and cardiac surgery products while serving the same surgeon customer base.
• Abbott: Major cardiovascular and structural heart player (via Abbott Vascular) with overlapping offerings in aortic interventions, heart valves, and vascular closure. Targets cardiac surgeons and interventionalists with a comparable procedural focus to Artivion's aortic franchise.
• Boston Scientific: Major cardiovascular and peripheral intervention player with structural heart, atherectomy, and vascular access products. Overlaps with Artivion's procedural cardiology and peripheral stent franchises within hospital accounts.
• Getinge: Global surgical and cardiovascular medtech provider (including Maquet cardiac surgery products). Competes with Artivion across cardiac surgery perfusion, vascular grafts, and operating-room disposables in the same hospital accounts.

Direct peers

• Edwards Lifesciences: Structural heart specialist with leadership in tissue heart valves and transcatheter valves (TAVR). Directly comparable to Artivion's On-X mechanical valves and CryoValve allograft lines, serving cardiac surgeons treating aortic and mitral disease.
• Terumo Aortic: Aortic-focused division of Terumo offering stent grafts and hybrid devices for arch and thoracoabdominal repair (including Frozen Elephant Trork and custom solutions). Direct head-to-head competitor to Artivion's NEXUS, E-vita, and E-nside platforms in complex aortic surgery.
• W. L. Gore & Associates: Manufacturer of GORE TAG thoracic endoprostheses and other aortic/vascular stent grafts. Competes with Artivion across thoracic and abdominal aortic aneurysm repair and shares the same vascular surgeon customer base.
• Cook Medical: Broad vascular and aortic device manufacturer with thoracoabdominal and abdominal stent graft systems. Competitor to Artivion's E-xtra, E-nside, E-tegra, and E-liac products, selling into similar vascular surgery accounts globally.
• LivaNova: Cardiac surgery and neuromodulation company offering tissue heart valves and other cardiac surgery products directly comparable to Artivion's heart valve franchise (On-X and CryoValve), serving the same surgical specialty.

Emerging players

• Endologix: Pure-play abdominal and thoracic aortic aneurysm (AAA/TAA) stent graft developer. A more focused competitor to Artivion's E-tegra, E-liac, and Artivex abdominal and thoracic stent graft portfolios.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cryolife
• Facebookfacebook.com/101851570799
• LinkedInlinkedin.com/company/cryolife-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Artivion